WO1996009395A3 - Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies - Google Patents

Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies Download PDF

Info

Publication number
WO1996009395A3
WO1996009395A3 PCT/EP1995/003726 EP9503726W WO9609395A3 WO 1996009395 A3 WO1996009395 A3 WO 1996009395A3 EP 9503726 W EP9503726 W EP 9503726W WO 9609395 A3 WO9609395 A3 WO 9609395A3
Authority
WO
WIPO (PCT)
Prior art keywords
ipp
immune
auto
diseases
humans
Prior art date
Application number
PCT/EP1995/003726
Other languages
German (de)
English (en)
Other versions
WO1996009395A2 (fr
Inventor
Thomas Franz Ferdinand Meyer
Johannes Pohlner
Susanne Christine Beck
Joachim Jose
Uwe Woelk
Dirk R Lorenzen
Karin Brigitte Oetzelberger
Original Assignee
Max Planck Gesellschaft
Thomas Franz Ferdinand Meyer
Johannes Pohlner
Susanne Christine Beck
Joachim Jose
Uwe Woelk
Dirk R Lorenzen
Oetzelfberger Karin Brigitte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Thomas Franz Ferdinand Meyer, Johannes Pohlner, Susanne Christine Beck, Joachim Jose, Uwe Woelk, Dirk R Lorenzen, Oetzelfberger Karin Brigitte filed Critical Max Planck Gesellschaft
Priority to AU36515/95A priority Critical patent/AU3651595A/en
Publication of WO1996009395A2 publication Critical patent/WO1996009395A2/fr
Publication of WO1996009395A3 publication Critical patent/WO1996009395A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La présente invention concerne des médicaments et des agents de diagnostic, ainsi que des procédés diagnostiques, thérapeutiques et prophylactiques pour le traitement de maladies auto-immunes et virales chez l'homme, lesdites maladies pouvant être causées par des bactéries pathogènes. Ces bactéries sont, en particulier, des micro-organismes qui colonisent les muqueuses de l'homme et sécrètent certaines exoprotéines présentant des similitudes structurelles avec les protéines humaines. Les protéines similaires à la protéase IgA, qui sont particulièrement bien absorbées par les cellules et se présentent sous forme d'antigènes sur les molécules de CMH, ont une importance particulière dans ce contexte. La polyprotéine de la protéase IgA (IPP) de neisseria pathogènes présente une homologie particulièrement marquée avec les protéines humaines. Par exemple, un peptide déterminé de l'IPP présente une homologie marquée avec les protéines articulaires de liaison et Aggrekan. Il est donc prouvé, par exemple, que l'IPP est un agent étiologique de la polyarthrite rhumatoïde (RA). La réaction auto-immune est en outre favorisée par d'autres propriétés des neisseria produisant l'IPP et des IPP. L'aptitude de l'IPP à activer les virus et les éléments viraux constitue une propriété importante. Cela concerne en particulier l'activation de rétrovirus proviraux et de rétrovirus endogènes chez l'homme. D'autres réactions auto-immunes chez l'homme sont induites par l'activation de virus et d'éléments viraux. En outre, le développement du syndrome d'immunodéficience acquise (SIDA) s'explique également par l'activité du provirus VIH dépendant de l'IPP. Les propriétés, décrites dans l'invention, des neisseria pathogènes et des IPP ainsi formées, permettent de développer de nombreux procédés diagnostiques, thérapeutiques et prophylactiques nouveaux.
PCT/EP1995/003726 1994-09-21 1995-09-21 Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies WO1996009395A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36515/95A AU3651595A (en) 1994-09-21 1995-09-21 Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4433708 1994-09-21
DEP4433708.6 1994-09-21

Publications (2)

Publication Number Publication Date
WO1996009395A2 WO1996009395A2 (fr) 1996-03-28
WO1996009395A3 true WO1996009395A3 (fr) 1996-07-18

Family

ID=6528818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003726 WO1996009395A2 (fr) 1994-09-21 1995-09-21 Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies

Country Status (2)

Country Link
AU (1) AU3651595A (fr)
WO (1) WO1996009395A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443147A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acide nucleique et proteine correspondante intitulee 184p1e2, utilises dans le traitement et la detection de cancers

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254090A1 (fr) * 1986-07-02 1988-01-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour obtenir des protéines par génie génétique en utilisant des cellules-hôtes gram-négatives
WO1990011367A1 (fr) * 1989-03-17 1990-10-04 Mogens Kilian PROTEASES D'IMMUNOGLOBULINE A1 (PROTEASES IgA1), PROCEDE DE PRODUCTION PAR GENIE GENETIQUE DE CE TYPE D'ENZYME ET VACCINS CONTENANT LES ENZYMES AINSI QUE DES FRAGMENTS DE CELLES-CI POUR L'IMMUNISATION CONTRE LA MENINGITE BACTERIENNE AINSI QUE D'AUTRES MALADIES PROVOQUEES PAR DES BACTERIES PRODUCTRICES DE PROTEASES IgA1
WO1991011520A1 (fr) * 1990-02-03 1991-08-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. PROCEDE DE CLIVAGE ENZYMATIQUE DE PROTEINES RECOMBINANTES AU MOYEN DE PROTEASES D'IgA
EP0495398A1 (fr) * 1991-01-11 1992-07-22 Roche Diagnostics GmbH Protéase IgA recombinante
WO1992013871A1 (fr) * 1991-01-31 1992-08-20 Washington University Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene
WO1992016643A1 (fr) * 1991-03-14 1992-10-01 Imclone Systems Incorporated Epitopes de porine hybrides de recombinaison
WO1994006421A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Vaccin a proteine m multivalente recombinee

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254090A1 (fr) * 1986-07-02 1988-01-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour obtenir des protéines par génie génétique en utilisant des cellules-hôtes gram-négatives
WO1990011367A1 (fr) * 1989-03-17 1990-10-04 Mogens Kilian PROTEASES D'IMMUNOGLOBULINE A1 (PROTEASES IgA1), PROCEDE DE PRODUCTION PAR GENIE GENETIQUE DE CE TYPE D'ENZYME ET VACCINS CONTENANT LES ENZYMES AINSI QUE DES FRAGMENTS DE CELLES-CI POUR L'IMMUNISATION CONTRE LA MENINGITE BACTERIENNE AINSI QUE D'AUTRES MALADIES PROVOQUEES PAR DES BACTERIES PRODUCTRICES DE PROTEASES IgA1
WO1991011520A1 (fr) * 1990-02-03 1991-08-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. PROCEDE DE CLIVAGE ENZYMATIQUE DE PROTEINES RECOMBINANTES AU MOYEN DE PROTEASES D'IgA
EP0495398A1 (fr) * 1991-01-11 1992-07-22 Roche Diagnostics GmbH Protéase IgA recombinante
WO1992013871A1 (fr) * 1991-01-31 1992-08-20 Washington University Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene
WO1992016643A1 (fr) * 1991-03-14 1992-10-01 Imclone Systems Incorporated Epitopes de porine hybrides de recombinaison
WO1994006421A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Vaccin a proteine m multivalente recombinee

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARZESE ET AL: "COMPARITIVE STUDIES OF THE IGA1 PROTEASE GENES FROM HAEMOPHILUS INFLUENZAE,NEISSERIA GONORRHOEAE,AND PREVOTELLA MELANINOGENICA", CLINICAL INFECTIOUS DISEASES, vol. 20, no. S2, June 1995 (1995-06-01), pages S169 - S171, XP002003047 *
HALTER ET AL: "IGA PROTEASE OF NEISSERIA GONORRHOEAE: ISOLATION AND CHARACTERIZATION OF THE GENE AND ITS EXTRACELLULAR PRODUCT", THE EMBO JOURNAL, vol. 3, no. 7, 1984, pages 1595 - 1601, XP002003042 *
KLAUSER ET AL: "EXTRACELLULAR TRANSPORT OF CHOLERA TOXIN B SUBUNIT USING NEISSERIA IGA PROTEASE BETA-DOMAIN:CONFORMATION- DEPENDENT OUTER MEMBRANE TRANSLOCATION", THE EMBO JOURNAL, vol. 9, no. 6, 1990, pages 1991 - 1999, XP002003041 *
LOMHOLT ET AL: "COMPARITIVE CHARACTERIZATION OF THE IGA GENE ENCODING IGA1 PROTEASE IN NEISSERIA MENINGITIDIS, NEISSERIA GONORRHOEAE AND HAEMOPHILUS INFLUENZAE", MOLECULAR MICROBIOLOGY, vol. 15, no. 3, 1995, pages 495 - 506, XP002003045 *
LOMHOLT ET AL: "SIGNIFICANTLY DIFFERENT DEGREES OF ANTIGENIC HETEROGENEITY AMONG IGA1 PROTEASES SECRETED BY SPECIES OF STREPTOCOCCUS,NEISSERIA AND HAEMOPHILUS", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 248, XP002003048 *
POHLNER ET AL: "GENE STRUCTURE AND EXTRACELLULAR SECRETION OF NEISSERIA GONORRHOEAE IGA PROTEASE", NATURE, vol. 325, 1987, pages 458 - 462, XP002003040 *
POHLNER ET AL: "SEQUENCE-SPECIFIC CLEAVAGE OF PROTEIN FUSIONS USING A RECOMBINANT NEISSERIA TYPE 2 IGA PROTEASE", BIO/TECHNOLOGY, vol. 10, 1992, pages 799 - 804, XP002003043 *
POHLNER ET AL: "UPTAKE AND NUCLEAR TRANSPORT OF NEISSERIA IGA1 PROTEASE- ASSOCIATED ALPHA-PROTEINS IN HUMAN CELLS", MOLECULAR MICROBIOLOGY, vol. 17, no. 6, 1995, pages 1073 - 1083, XP002003046 *
POULSEN ET AL: "PRIMARY STRUCTURE OF NEISSERIA MENINGITIDIS IGA1 PROTEASES IN RELATION TO CLEAVAGE SPECIFICITY", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 249, XP002003044 *

Also Published As

Publication number Publication date
AU3651595A (en) 1996-04-09
WO1996009395A2 (fr) 1996-03-28

Similar Documents

Publication Publication Date Title
BHAT et al. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275
EP1878742A3 (fr) Peptides VIH, antigènes, compositions de vaccin, immunoessai et procédé pour détecter des anticorps induits par le VIH
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
MXPA02007413A (es) Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
BG100455A (en) Hiv protease inhibitors
RU95110699A (ru) Устройство для обработки крови, озоновый генератор для производства озона, устройство для контакта газа и жидкости, способ инактивации вируса иммунодефицита человека в белковом материале
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
HU901585D0 (en) Method for treatment of viral infections using functional derivatives of icam-1
NO178768C (no) 11-aryl-4-östrener og antikonsepsjonsmidler inneholdende disse
Li et al. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
Plourde et al. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid
KR950010898A (ko) 재조합 사람 혈청 알부민 약제학적 제제의 멸균법
Agrawal et al. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity
WO1996009395A3 (fr) Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
Yu et al. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites
AU5061090A (en) Aids therapy
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
Essex et al. Antigenic characterization of the human immunodeficiency viruses
Luce The Acquired Immunodeficiency Syndrome: A report on the second international conference on AIDS
TR199700423A2 (xx) Bis-orto ikame edilmi� benzoilguanidin'ler, bunlar�n imal edilmesine mahsus usul, bunlar�n ila� ya da diyagnostik madde olarak kullan�lmalar� ve bunlar� ihtiva eden ila�lar.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA